Takeda sues Taiyo over product recalls
This article was originally published in Scrip
Takedahas filed a lawsuit seeking ¥2.8 billion ($26.9 million) in damages from fellow Japanese firm Taiyo Pharmaceutical Industry in relation to the contract manufacture of an injectable antibiotic. Two lots of Pansporin (cefotiam) made by Taiyo were recalled last year following the discovery of glass fragments in two vials. In an action brought with the Osaka district court, Takeda said it was seeking the damages for insufficient quality control procedures and record keeping with regard to the identification of potentially defective products. Takeda noted that the suit followed the failure of direct negotiations with Taiyo and that all of its injectable antibiotics were now made at an in-house plant in Japan.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.